Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Revenue (2016 - 2025)

Capricor Therapeutics has reported Revenue over the past 15 years, most recently at $12485.0 for Q1 2025.

  • Quarterly results put Revenue at $12485.0 for Q1 2025, down 99.88% from a year ago — trailing twelve months through Dec 2025 was $12485.0 (down 99.95% YoY), and the annual figure for FY2024 was $22.3 million, down 11.55%.
  • Revenue for Q1 2025 was $12485.0 at Capricor Therapeutics, down from $11.1 million in the prior quarter.
  • Over the last five years, Revenue for CAPR hit a ceiling of $12.1 million in Q4 2023 and a floor of $12485.0 in Q1 2025.
  • Median Revenue over the past 5 years was $2.6 million (2023), compared with a mean of $4.0 million.
  • Biggest five-year swings in Revenue: skyrocketed 1955.53% in 2023 and later crashed 99.88% in 2025.
  • Capricor Therapeutics' Revenue stood at $204082.0 in 2021, then soared by 370.35% to $959903.0 in 2022, then surged by 1159.3% to $12.1 million in 2023, then dropped by 7.92% to $11.1 million in 2024, then plummeted by 99.89% to $12485.0 in 2025.
  • The last three reported values for Revenue were $12485.0 (Q1 2025), $11.1 million (Q4 2024), and $2.3 million (Q3 2024) per Business Quant data.